- Home
- PFSI vs ITRM Comparison
PFSI vs ITRM Comparison
Compare PFSI & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFSI | ITRM |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.8B | 24.3M |
| IPO Year | 2018 | 2018 |
Fundamental Metrics
Financial Performance| Metric | PFSI | ITRM |
|---|---|---|
| Price | $90.08 | $0.03 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 2 |
| Target Price | ★ $137.25 | $9.00 |
| AVG Volume (30 Days) | 572.9K | ★ 24.8M |
| Earning Date | 04-21-2026 | 05-12-2026 |
| Dividend Yield | ★ 1.33% | N/A |
| EPS Growth | ★ 59.25 | 57.43 |
| EPS | ★ 9.30 | N/A |
| Revenue | ★ $984,629,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.02 | $947.65 |
| P/E Ratio | $9.69 | ★ N/A |
| Revenue Growth | ★ 3.05 | N/A |
| 52 Week Low | $82.65 | $0.03 |
| 52 Week High | $160.36 | $1.42 |
Technical Indicators
Market Signals| Indicator | PFSI | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 50.53 | 26.10 |
| Support Level | $88.57 | N/A |
| Resistance Level | $104.38 | $0.39 |
| Average True Range (ATR) | 2.65 | 0.02 |
| MACD | 1.31 | -0.01 |
| Stochastic Oscillator | 93.59 | 3.34 |
Price Performance
Historical ComparisonAbout PFSI PennyMac Financial Services Inc.
PennyMac Financial Services Inc is a specialty financial services firm with a comprehensive mortgage platform and integrated business focused on the production and servicing of U.S. residential mortgage loans. The company operates through two segments: production and servicing. The production segment performs loan origination, acquisition and sale activities. The servicing segment performs loan servicing for newly originated loans.
About ITRM Iterum Therapeutics plc
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.